Globally-recognized physicians, scientists, and national security practitioners that develop and deliver cutting edge capabilities across the life sciences.
Medical and Scientific Leadership
|
Mark Boguski, MD, Ph.DChief Medical Officer
BIO
Dr. Mark Boguski is a pioneer in the fields of Bioinformatics, Genomics and Precision Medicine and has broad experience in government, academia and industry. He served on the faculties of Harvard Medical School and Beth Israel Deaconess Medical Center where he founded the Genomic Medicine Initiative in 2009. He has held faculty positions at the Johns Hopkins University School of Medicine, the Fred Hutchinson Cancer Research Center and the U.S. National Institutes of Health. Dr. Boguski also served as Vice President of the Novartis Institute for Biomedical Research and as the founding Director of the Paul Allen Institute for Brain Science. He has been an adviser to numerous companies and medical research organizations. Dr. Boguski received the Regents' Award from the National Library of Medicine and the Director's Award from the National Institutes of Health. He is an elected member of the National Academy of Medicine, an honorary Fellow of the College of American Pathologists, a Fellow of the American College of Medical Informatics, a former reviewing editor for Science magazine and past Editor-in-Chief of Genomics. Podcasts
|
|
Jose Morey, MD, Ph.DChief Medical Innovation Officer
BIO
Dr. José M. Morey, M.D., is a clinical radiologist who is passionate about harnessing technology, artificial intelligence and innovation to improve the human condition. Dr. Morey has served as Associate Chief Health Officer with IBM Watson Health, Chief Innovation Officer for Hyperloop Transportation Technologies and the Medical Technology and Artificial Intelligence Advisor for NASA iTech. Dr. Morey holds academic professorships at the University of Virginia and Singularity University. Dr. Morey is a nationally recognized voice in the innovation and technology sector. He is known for his expertise regarding the role of Artificial Intelligence and healthcare, and how this new technology will transform patient care. His work also extends beyond healthcare, remaining squarely focused on cutting edge research and its application to large scale endeavors on Earth and in space. Dr. Morey has been a stalwart advocate of a strong STEM education program because of the profound impact it has on our society. This emphasis on education keeps our nation at the forefront of research and development and generates better conditions for society, as it serves as an engine for economic development and improved quality of life. |
|
Kyle Landry, Ph.D.Chief Scientist, Expeditionary and Special Programs Laboratory
BIO
Dr. Kyle Landry manages and directs all core research groups within the laboratory and helps with the commercial development of Liberty’s technologies. He is experienced in isolating novel compounds, delivery systems, rapid pathogen detection, and enzymology. Dr. Landry received his PhD in food microbiology from the University of Massachusetts Amherst and held a post-doctoral position in the Department of Genetics at Harvard Medical School. He is also a junior faculty member in the Department of Health and Rehabilitation Sciences at Boston University. Honors, Awards, and Memberships
|
|
Lynn Turgiss Nosek, MSLab Manager, Expeditionary and Special Programs Laboratory
BIO
Lynn Turgiss Nosek leads the X-Lab team with her experience as a Scientist in Clinical Affairs, Research and Development, Quality, Regulatory and Manufacturing. She has assisted with multiple 510(k) medical device filings and EU regulatory filings. She aslo has expertise in with assay development, reagent development, verification and validation processes in hemostasis, critical care, and vaccine areas. |
International Leadership
|
Jonathan (Jon) SurbeckOperating Officer and Government Liaison
Australia BIO
Jon Surbeck is a former Australian Army Officer with an extensive operational background both overseas and domestically. His service in the Army includes several representational overseas postings. Jon manages our programs in Australia. |
Executive Leadership
|
Mike HarrisChief Strategy Officer
BIO
Mike Harris is a former senior government official and former United States Marine Corps Officer with a background in biological sciences. With over three decades managing numerous large-scale government programs across the globe, Mike oversees Liberty's long-range planning and program management. |
|
Suzanne Bakewell, Ph.DChief Compliance Officer
BIO
Dr. Suzanne Bakewell’s expertise comes from consulting for biotech companies, the pharmaceutical industry, for principal investigators in Academia, start-ups, and UN-supported NGO’s. Her work has included drug development, translational research in Oncology, regulatory affairs, medical and grant writing, and forging mutually profitable collaborations. |
|
Mathew Easterday, JD, Ph.DGeneral Counsel
BIO
Mathew Easterday guides Liberty’s legal operations and transnational innovation strategy. Matt’s years of legal and scientific experience in Silicon Valley and in research laboratories across the globe ensures that Liberty’s integrated life science solutions are unequaled in their quality, integrity, and innovation. |
|
Jason AndersonCo-Founder, Chief Executive Officer
BIO
Jason Anderson leads Liberty’s multidisciplinary teams by drawing upon his more than a decade and a half of diplomatic experience across the globe. He is the recipient of numerous U.S. government awards and is a joint inventor on patents that describe how genetic information can be secured, encrypted and transmitted. |
|
Sean RileyChief Business Officer
BIO
Sean Riley is a former senior government member with an extensive background in national security operations and advanced certifications in Program Development and Management. |
Senior Board Advisors
|
BIO
Edward Schulak is a philanthropist, architect, entrepreneur, inventor, international business leader and a director and benefactor of numerous genetic, life science and pharmaceutical companies. Ed’s enterprises have shaped the international marketplace while his service on numerous charitable, academic, and business boards have fostered innovation and intellectual inquiry across the globe. |
Edward Shulak
Co-Founder, Chairman
Aristides Patrinos, Ph.DBIO
Dr. Patrinos is the former Director of the Office of Biological and Environmental Research in the United States Department of Energy, where he was a leader in the Human Genome Project. His work and research has defined many of the policies the United States employs with regard to the fields of genomics and biology. |
James Cole, JDBIO
James Cole is the former Deputy Attorney General of the United States. Jim leverages his policy experience to ensure that Liberty's capabilities are positioned to address global challenges. |
Lon AugustenborgBIO
Lon Augustenborg led the CIA’s largest domestic office and served as Chief of Station in CIA’s flag ship locations across East Asia and Latin America as well as Chief of Operations for CIA’s Counterintelligence Center. After a 35-years of tenure, Lon retired as a member of the Senior Intelligence Service. |
Rajendra Apte, MD, Ph.DBIO
Dr. Raj Apte is a Paul A. Cibis Distinguished Professor in the Department of Ophthalmology & Visual Science and is Director of Translational Research at Washington University School of Medicine. Raj is one of America's leading surgeons and researchers into the human eye, whose innovations enhance optical capability while mitigating threats from both injury and disease. |
Carlos Bustamante Ph.D.BIO
Carlos Bustamante is the former Chair of the Department of Biomedical Data Science at Stanford University and is considered one of America's leading population geneticists. Carlos joined F-Prime as a Venture partner in January of 2019 to identify new opportunities at the intersection of genomics, global health, and data science. |
Todd Dickinson Ph.D.BIO
Todd Dickinson is the CEO of EdenRoc Sciences’ ArcBio and Dovetail Genomics companies, both global leaders in infectious disease characterization and the production of high-resolution genomic assemblies. Todd was a founding scientist at Illumina where he directed programs in optical chemical detection, the design and development of the early array formats used in Illumina's industry-leading BeadArray® microarray product lines, and several major strategic programs aimed at developing future-generation sequencing platforms. |
David Armstrong MD, DPM, Ph.DBIO
Dr. David Armstrong is Professor of Clinical Surgery at the University of Southern California. He is founder and co-director of the Southwestern Academic Limb Salvage Alliance (SALSA). Dr. Armstrong was selected as one of the first six International Wound Care Ambassadors and is the recipient of numerous awards including the inaugural Georgetown Distinguished Award for Diabetic Limb Salvage. In 2008, he was the 25th and youngest-ever member elected into the Podiatric Medicine Hall of Fame. |
David Sinclair, Ph.DBIO
Dr. David Sinclair is a Professor at Harvard Medical School and Director of the Paul F. Glenn Laboratory for Aging Research. David is one of the world's leading geneticists in the field of human longevity and the diseases of aging. He was awarded an Order of Australia in 2018 in recognition of his work and was named to Time’s 100 list of most influential people in the world in 2014. |
Expeditionary Sciences and Special Programs Laboratory
Liberty's Expeditionary and Special Programs Laboratory (X-Lab) leverages the combined power of precision medicine and bioinformatics to develop novel biology-based breakthroughs that result in new medicines and biological capabilities for healthcare, industry, space exploration agencies, and governments across the globe.
Keith Ballard, Ph.D.Biochemistry Group Lead
|
Biochemistry Group
The Biochemistry and Molecular Biology Group is responsible for the identification, development and characterization of biological therapeutics and innovative technologies within the company’s extensive portfolio of owned and exclusively licensed biology. The team uses a broad range of unique biochemistry capabilities, in conjunction with recombinant gene expression, to refine, isolate and purify biomolecules of interest from complex, and in many cases, novel biological mixtures. This group is also responsible for assessing the quality of our proprietary bio-products using standardized enzyme activity assays, spectroscopic analysis, as well as other biophysical and biochemical techniques. The Lab works closely with clients to build custom-tailored technologies that outperform products available through competitors or create novel product lines. The Biochemistry and Molecular Biology group provides expertise in proteomics experimental design and analysis as part of an integrated systems biology pipeline to derive technologies and products from innovative biological and biochemical processes. |
|
Applied research Group
The Applied Research Group at Liberty BioSecurity develops engineering solutions that ensure the stability and efficacy of innovative biological products developed within Liberty BioSecurity. Drawing upon a multidisciplinary team of scientists with decades of industry expertise, the applied research group designs the tools required to stress Liberty’s products under 'real world' application scenarios in the clinic, in support of space missions, and for governments seeking to mitigate the threats posed by naturally occurring and man-made biological threats. The solutions developed by this team allow Liberty's customers to deploy these new biological products in the most challenging of conditions or tailor them to the individual needs of patients, physicians, engineers or national security practitioners. |
Mark Doolittle, MSApplied Research Group Lead
|
Tim Avery, MSProduction Group Lead
|
PRODUCTION GROUP
The Production group at Liberty Biosecurity is responsible for the manufacturing of our biological products. They are also in charge of quality control testing. |
ExplorAtory Group
The Exploratory Group is the pure research and development arm of Liberty BioSecurity. The group is charged with pushing the boundaries of science and engineering to develop next generation biological products for Liberty. With exclusive access to novel biology collections obtained by governments and academic communities across the globe, the exploratory group employs rapid proprietary screening methodologies to assess the commercial viability and product potential of novel chemical and biological compounds. This interdisciplinary team of scientists and bioinformaticians work together to demonstrate preliminary efficacy of new products derived from novel biological species.
Bioinformatics Group
The bioinformatics group utilizes the latest advances in sequencing technology, coupled with capabilities derived from Liberty’s own Bioinformatics Department, to support Liberty's bioengineering and medical activities. With extensive expertise in big data, the bioinformatics group can process, curate and optimize large data sets for use with proprietary algorithms and artificial intelligence pipelines. Through the use of their unique in silico bioinformatic pipelines, the team extracts unique forms of metadata that in turn result in discoveries as varied as the identification of new organisms, to screening for new mutations within the human genome, to finding entirely new genes that will be the foundation of next-generation classes of drugs and bioengineering solutions.
|
|